Early observations and pilot data that first suggested a new direction
Status epilepticus — prolonged seizures lasting >5 minutes — is a neurological emergency with mortality of 10-30%. The VA Cooperative Study (Treiman 1998) established lorazepam as the optimal first-line benzodiazepine for convulsive status epilepticus. After first-line benzodiazepines, phenytoin/fosphenytoin had been the default second-line agent for decades, primarily through historical precedent rather than comparative trial evidence. Levetiracetam and valproate offered potential advantages (fewer drug interactions, easier dosing) but lacked head-to-head comparison.
Landmark RCTs and pivotal trials that established the evidence base
ESETT (2019) was the definitive trial: a randomised comparison of levetiracetam, fosphenytoin, and valproate as second-line agents for benzodiazepine-refractory status epilepticus in 384 patients. The result was decisive in its equivalence — seizure cessation without rescue medication occurred in 47% (levetiracetam), 45% (fosphenytoin), and 46% (valproate), with no significant differences between any pair. This effectively liberated clinicians from phenytoin as the mandatory second-line choice.
Follow-up studies, subgroup analyses, and real-world validation
RAMPART (2012) had previously established intramuscular midazolam as non-inferior to intravenous lorazepam for prehospital status epilepticus, with seizure cessation in 73.4% versus 63.4%. This was significant because IM injection could be given immediately by paramedics without IV access, reducing time to treatment. Together, RAMPART and ESETT reshaped the entire status epilepticus treatment algorithm from first contact through second-line therapy.
Integration into clinical practice guidelines and recommendations
The American Epilepsy Society incorporated ESETT results into status epilepticus treatment algorithms, confirming levetiracetam and valproate as acceptable alternatives to fosphenytoin. Many centres adopted levetiracetam as the preferred second-line agent due to its simpler dosing, fewer drug interactions, and lower risk of cardiovascular adverse effects compared to phenytoin.
AES Status Epilepticus Guidelines
Updated with ESETT: levetiracetam, fosphenytoin, and valproate are equivalent second-line options
Now
Current standard of care and ongoing research directions
The ESETT result — that all three agents are equivalent — has paradoxically simplified clinical practice. Centres can choose based on individual patient factors, drug availability, and side effect profiles rather than adhering to a single default agent. Current research focuses on third-line agents for refractory status epilepticus, which remains a significant unmet need with mortality exceeding 30%.
What is the best second-line drug for status epilepticus?+
The ESETT trial (2019, N=384) definitively showed that levetiracetam, fosphenytoin, and valproate are equivalent second-line agents for benzodiazepine-refractory status epilepticus, with seizure cessation rates of 45-47% for each. Clinicians can choose based on individual patient factors.
Can status epilepticus be treated before reaching the hospital?+
Yes. The RAMPART trial (2012, N=893) showed intramuscular midazolam was non-inferior — and in some analyses superior — to intravenous lorazepam for prehospital seizure cessation (73.4% vs 63.4%). IM injection can be given immediately without IV access, reducing critical time to treatment.
